Intrathecal substance P-saporin for the treatment of intractable cancer pain

Hugh Nymeyer; Douglas A. Lappi; Denise Higgins; Carl E. Noe; Arthur E. Frankel

doi:10.1007/978-3-319-27607-6_13

Intrathecal substance P-saporin for the treatment of intractable cancer pain

Hugh Nymeyer, Douglas A. Lappi, Denise Higgins, Carl E. Noe, Arthur E. Frankel

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Substance P-saporin (SP-SAP) has covalent bonds between the biological toxin, saporin (SAP), and the endogenous peptide, substance P (SP). SAP targets the toxin to the subset of neurons expressing the NK1 receptor. SP-SAP is currently in a phase I clinical trial and is unique as it is the only targeted toxin for pain to undergo human testing. This chapter reviews the history of SP-SAP and related NK1-receptor targeted toxins, animal data on the safety and efficacy of SP-SAP for the treatment of pain (in light of the results of NK1 receptor antagonists and knockouts/knockdowns of either SP or the NK1 receptor), and mechanisms of action of SP-SAP.

Original language	English (US)
Title of host publication	Techniques of Neurolysis
Publisher	Springer International Publishing
Pages	197-206
Number of pages	10
ISBN (Electronic)	9783319276076
ISBN (Print)	9783319276052
DOIs	https://doi.org/10.1007/978-3-319-27607-6_13
State	Published - Jan 1 2016

Keywords

Allodynia pain
Hyperalgesia
NK1
SP-SAP
Substance p

ASJC Scopus subject areas

General Medicine

Access to Document

10.1007/978-3-319-27607-6_13

Cite this

@inbook{de1e359a8a0a45c68fee0f905cc8934f,

title = "Intrathecal substance P-saporin for the treatment of intractable cancer pain",

abstract = "Substance P-saporin (SP-SAP) has covalent bonds between the biological toxin, saporin (SAP), and the endogenous peptide, substance P (SP). SAP targets the toxin to the subset of neurons expressing the NK1 receptor. SP-SAP is currently in a phase I clinical trial and is unique as it is the only targeted toxin for pain to undergo human testing. This chapter reviews the history of SP-SAP and related NK1-receptor targeted toxins, animal data on the safety and efficacy of SP-SAP for the treatment of pain (in light of the results of NK1 receptor antagonists and knockouts/knockdowns of either SP or the NK1 receptor), and mechanisms of action of SP-SAP.",

keywords = "Allodynia pain, Hyperalgesia, NK1, SP-SAP, Substance p",

author = "Hugh Nymeyer and Lappi, {Douglas A.} and Denise Higgins and Noe, {Carl E.} and Frankel, {Arthur E.}",

note = "Publisher Copyright: {\textcopyright} Springer International Publishing Switzerland 2016.",

year = "2016",

month = jan,

day = "1",

doi = "10.1007/978-3-319-27607-6_13",

language = "English (US)",

isbn = "9783319276052",

pages = "197--206",

booktitle = "Techniques of Neurolysis",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Intrathecal substance P-saporin for the treatment of intractable cancer pain

AU - Nymeyer, Hugh

AU - Lappi, Douglas A.

AU - Higgins, Denise

AU - Noe, Carl E.

AU - Frankel, Arthur E.

N1 - Publisher Copyright: © Springer International Publishing Switzerland 2016.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Substance P-saporin (SP-SAP) has covalent bonds between the biological toxin, saporin (SAP), and the endogenous peptide, substance P (SP). SAP targets the toxin to the subset of neurons expressing the NK1 receptor. SP-SAP is currently in a phase I clinical trial and is unique as it is the only targeted toxin for pain to undergo human testing. This chapter reviews the history of SP-SAP and related NK1-receptor targeted toxins, animal data on the safety and efficacy of SP-SAP for the treatment of pain (in light of the results of NK1 receptor antagonists and knockouts/knockdowns of either SP or the NK1 receptor), and mechanisms of action of SP-SAP.

AB - Substance P-saporin (SP-SAP) has covalent bonds between the biological toxin, saporin (SAP), and the endogenous peptide, substance P (SP). SAP targets the toxin to the subset of neurons expressing the NK1 receptor. SP-SAP is currently in a phase I clinical trial and is unique as it is the only targeted toxin for pain to undergo human testing. This chapter reviews the history of SP-SAP and related NK1-receptor targeted toxins, animal data on the safety and efficacy of SP-SAP for the treatment of pain (in light of the results of NK1 receptor antagonists and knockouts/knockdowns of either SP or the NK1 receptor), and mechanisms of action of SP-SAP.

KW - Allodynia pain

KW - Hyperalgesia

KW - NK1

KW - SP-SAP

KW - Substance p

UR - http://www.scopus.com/inward/record.url?scp=84978312643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978312643&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-27607-6_13

DO - 10.1007/978-3-319-27607-6_13

M3 - Chapter

AN - SCOPUS:84978312643

SN - 9783319276052

SP - 197

EP - 206

BT - Techniques of Neurolysis

PB - Springer International Publishing

ER -

Intrathecal substance P-saporin for the treatment of intractable cancer pain

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this